Exhibit 99.1

Contact: Merilee Raines, Chief Financial Officer, (207) 856-8155

FOR IMMEDIATE RELEASE

IDEXX Laboratories Announces Second Quarter Results

WESTBROOK, Maine, July 29, 2005 — IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenue for the second quarter of 2005 increased 17% to $160.6 million from $137.4 million for the second quarter of 2004. Earnings per diluted share for the quarter ended June 30, 2005 were $0.59, compared to $0.66 for the same period in the prior year.  Earnings per diluted share for the quarter were $0.01 above the guidance of $0.56 to $0.58 per share given by the Company upon announcement of its first quarter results. 

          During the quarter ended June 30, 2004, the Company’s earnings per diluted share included a net benefit of $0.07 resulting from (i) a reduction in the Company’s provision for income taxes primarily related to the completion of an IRS audit through the year 2001, (ii) a reduction in the estimated liability for a third party claim, and (iii) a payment received in settlement of certain litigation. During the quarter ended June 30, 2005, the Company incurred acquisition integration costs of $0.01 per diluted share associated with the acquisitions of Vet Med Lab and Dr. Bommeli AG in the fourth quarter of 2004. Excluding the effects of these discrete costs in the second quarters of 2005 and 2004, adjusted earnings per diluted share grew approximately 2%. 

          Companion Animal Group (CAG) revenue for the second quarter of 2005 increased 17% to $131.3 million from $112.7 million for the second quarter of 2004. This increase resulted primarily from increased sales of laboratory and consulting services, instruments and consumables, and, to a lesser extent, rapid assay products, and computer systems and digital radiography. The increase in laboratory and consulting services revenue was due, in part, to the inclusion of sales from laboratories acquired during 2004 and 2005, which contributed approximately 7% to CAG revenue growth during the quarter. The favorable impact of foreign currency contributed 1% to CAG revenue growth.

          Water segment revenue for the second quarter increased 10% to $14.3 million from $13.0 million for the second quarter of 2004 primarily due to higher sales volume. The favorable impact of foreign currency contributed 2% to Water revenue growth.

          Food Diagnostics Group (FDG) revenue for the second quarter increased 29% to $15.0 million from $11.6 million for the second quarter of 2004. This increase reflects growth in the production animal products business due to sales from businesses acquired in 2004 and higher sales volume of existing product lines. In addition, the impact of foreign currency contributed 3% to FDG revenue growth.

IDEXX Announces Second Quarter Results
July 29, 2005
Page 2 of 7

          “Our second quarter financial performance was essentially in-line with our expectations and plan,” said Jonathan Ayers, Chairman and CEO. “The revenue increase was driven by sales from European businesses acquired in late 2004, as well as by organic growth from several lines of business, including laboratory services, instruments and consumables, and production animal products. As anticipated, several factors caused our net income to fall below net income for the 2004 period. Some of these factors were discrete items applicable to both the 2004 and 2005 periods, and others reflect investments we are making to drive long-term growth.”

Year-to-date results

          Year-to-date revenue increased 16% to $313.1 million from $270.8 million for the same period in 2004. Year-to-date earnings per diluted share were $1.10, compared to $1.14 for the same period in the prior year. Excluding the effects of the tax, third party claim and litigation related items in the six months ended June 30, 2004, discussed above, and integration costs incurred in the six months ended June 30, 2005 of $0.03 per diluted share, adjusted earnings per diluted share increased 6%.

          Companion Animal Group (CAG) revenue for the six months ended June 30, 2005 increased 15% to $256.2 million from $222.6 million. This increase resulted primarily from increased sales of laboratory and consulting services, instruments and consumables, and, to a lesser extent, rapid assay products, pharmaceutical products, and computer systems and digital radiography. The favorable impact of currency contributed 1% to year-to-date CAG revenue growth.

          Water segment revenue for the six months ended June 30, 2005 increased 9% to $27.1 million from $24.9 million primarily due to higher worldwide sales volume. The favorable impact of foreign currency contributed 2% to year-to-date Water revenue growth. 

          Food Diagnostics Group (FDG) revenue for the six months ended June 30, 2005 increased 27% to $29.8 million from $23.4 million for the same period in 2004. This increase reflects growth in the production animal products business due to sales from businesses acquired in 2004 and higher sales volume of existing product lines. The favorable impact of foreign currency contributed 3% to FDG revenue growth.

IDEXX Announces Second Quarter Results
July 29, 2005
Page 3 of 7

Outlook

The Company offers the following guidance for the third quarter of 2005:

• Revenue is expected to be approximately $155 to $157 million.

• Diluted earnings per share are expected to be approximately $0.57 to $0.59, which includes approximately $0.01 of anticipated acquisition integration costs.

The Company offers the following guidance for the full year of 2005:

• Revenue is expected to be approximately $625 to $630 million. The reduction from the Company’s prior guidance of $630 to $640 million is substantially the result of the strengthening of the U.S. dollar against major international currencies.

• Diluted earnings per share are expected to be approximately $2.26 to $2.29, which includes approximately $0.05 of anticipated acquisition integration costs. This is an increase of $0.01 from the Company’s prior guidance due to the performance in the second quarter.

About IDEXX Laboratories

          IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements

This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including  from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations.

IDEXX Announces Second Quarter Results
July 29, 2005
Page 4 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)

		Three Months Ended				Six Months Ended
		June 30, 2005		June 30, 2004		June 30, 2005		June 30, 2004
Revenue:	Revenue	$	160,630	$	137,379	$	313,056	$	270,796
Expenses and Income:	Cost of revenue		80,055		65,377		156,401		131,748
	Gross profit		80,575		72,002		156,655		139,048
	Sales and marketing		25,848		20,679		50,918		41,662
	General and administrative		15,846		11,583		30,944		23,825
	Research and development		9,995		8,685		19,769		17,205
	Income from operations		28,886		31,055		55,024		56,356
	Interest income, net		871		756		1,374		1,485
	Income before provision for income taxes and partner’s interest		29,757		31,811		56,398		57,841
	Partner’s share of consolidated loss		110		73		211		206
	Provision for income taxes		9,934		7,974		18,986		16,346
Net Income:	Net income	$	19,933	$	23,910	$	37,623	$	41,701
	Earnings per share: Basic	$	0.61	$	0.69	$	1.15	$	1.20
	Earnings per share: Diluted	$	0.59	$	0.66	$	1.10	$	1.14
	Shares outstanding: Basic		32,627		34,584		32,790		34,679
	Shares outstanding: Diluted		34,060		36,423		34,250		36,447

IDEXX Laboratories, Inc. and Subsidiaries
Key Operating Ratios (Unaudited)

		Three Months Ended						Six Months Ended
		June 30, 2005			June 30, 2004			June 30, 2005			June 30, 2004
Key Operating Ratios (as a percentage of revenue):	Gross profit		50.2	%		52.4	%		50.0	%		51.3	%
	Sales, marketing, general and administrative expense		26.0	%		23.5	%		26.1	%		24.1	%
	Research and development expense		6.2	%		6.3	%		6.3	%		6.4	%
	Income from operations		18.0	%		22.6	%		17.6	%		20.8	%
International Revenue:	International revenue		35.7	%		30.7	%		35.4	%		31.0	%

IDEXX Announces Second Quarter Results
July 29, 2005
Page 5 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Segment Information
Amounts in thousands (Unaudited)

		Three Months Ended						Six Months Ended
		June 30, 2005			June 30, 2004			June 30, 2005			June 30, 2004
Revenue:	Companion Animal Group	$	131,332		$	112,731		$	256,212		$	222,561
	Water		14,271			13,004			27,077			24,858
	Food Diagnostics Group		15,027			11,644			29,767			23,377
	Total	$	160,630		$	137,379		$	313,056		$	270,796
Gross Profit:	Companion Animal Group	$	62,825		$	56,109		$	122,088		$	108,185
	Water		9,622			8,748			18,099			16,741
	Food Diagnostics Group		8,128			7,145			16,468			14,122
	Total	$	80,575		$	72,002		$	156,655		$	139,048
Income from Operations:	Companion Animal Group	$	21,411		$	23,461		$	40,299		$	41,709
	Water		6,540			5,972			12,044			11,027
	Food Diagnostics Group		1,760			2,397			4,338			5,320
	Other		(825	)		(775	)		(1,657	)		(1,700	)
	Total	$	28,886		$	31,055		$	55,024		$	56,356
Gross Profit (as a percentage of revenue):	Companion Animal Group		47.8	%		49.8	%		47.7	%		48.6	%
	Water		67.4	%		67.3	%		66.8	%		67.3	%
	Food Diagnostics Group		54.1	%		61.4	%		55.3	%		60.4	%
Income from Operations (as a percentage of revenue):	Companion Animal Group		16.3	%		20.8	%		15.7	%		18.7	%
	Water		45.8	%		45.9	%		44.5	%		44.4	%
	Food Diagnostics Group		11.7	%		20.6	%		14.6	%		22.8	%

IDEXX Laboratories, Inc. and Subsidiaries
Revenues by Product and Service Categories
Amounts in thousands (Unaudited)

		Three Months Ended				Six Months Ended
		June 30, 2005		June 30, 2004		June 30, 2005		June 30, 2004
Net CAG Revenue:
	Instruments and consumables	$	53,045	$	48,424	$	105,918	$	97,235
	Rapid assay products		27,397		26,172		52,149		50,417
	Laboratory and consulting services		40,367		28,472		76,911		55,577
	Computer systems and digital radiography		7,199		6,591		14,660		13,919
	Pharmaceutical products		3,324		3,072		6,574		5,413
	Net CAG revenue		131,332		112,731		256,212		222,561
Net Water Revenue:	Water		14,271		13,004		27,077		24,858
Net FDG Revenue:
	Production animal products		10,956		7,585		21,818		15,483
	Dairy-testing products		4,071		4,059		7,949		7,894
	Net FDG revenue		15,027		11,644		29,767		23,377
Net Revenue:		$	160,630	$	137,379	$	313,056	$	270,796

IDEXX Announces Second Quarter Results
July 29, 2005
Page 6 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheet
Amounts in thousands (Unaudited)

		June 30, 2005			December 31, 2004
Assets:	Current Assets:
	Cash and cash equivalents	$	52,354		$	47,156
	Short-term investments		78,603			90,116
	Accounts receivable, net		73,139			65,639
	Inventories		81,765			76,424
	Other current assets		21,470			22,257
	Total current assets		307,331			301,592
	Long-term Investments		7,583			19,687
	Property and equipment - cost		143,082			137,851
	Less: accumulated depreciation		79,361			75,221
	Property and equipment, net		63,721			62,630
	Other long-term assets, net		121,615			130,328
	Total assets	$	500,250		$	514,237
Liabilities and Stockholders’ Equity:	Current Liabilities:
	Accounts payable	$	16,193		$	14,723
	Accrued expenses		68,093			73,785
	Notes payable		531			1,291
	Deferred revenue		8,434			10,153
	Total current liabilities		93,251			99,952
	Total long-term liabilities		14,538			16,233
	Partner’s interest in subsidiary		232			392
	Stockholders’ Equity:
	Common stock		4,559			4,522
	Additional paid-in capital		423,825			410,817
	Deferred equity-based compensation		1,231			665
	Retained earnings		356,305			318,682
	Treasury stock, at cost		(398,718	)		(348,327	)
	Accumulated other comprehensive income		5,027			11,301
	Total stockholders’ equity		392,229			397,660
	Total liabilities and stockholders’ equity	$	500,250		$	514,237

IDEXX Laboratories, Inc. and Subsidiaries
Key Balance Sheet Statistics (Unaudited)

		June 30, 2005		December 31, 2004
Key Balance Sheet Statistics:	Days sales outstanding		42		39
	Inventory turns		1.8		1.9

IDEXX Announces Second Quarter Results
July 29, 2005
Page 7 of 7

IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)

		Six Months Ended
		June 30, 2005			June 30, 2004
Operating:	Cash Flows from Operating Activities:
	Net income	$	37,623		$	41,701
	Non-cash charges		14,251			17,043
	Changes in current assets and liabilities, net of acquisitions and disposals		(13,789	)		(14,848	)
	Net cash provided by operating activities	$	38,085		$	43,896
Investing:	Cash Flows from Investing Activities:
	(Increase) decrease in investments, net		23,586			(268	)
	Purchase of property and equipment		(10,508	)		(17,676	)
	Acquisition of businesses and intangible assets		(659	)		(5,392	)
	Acquisition of equipment leased to customers		(1,278	)		(1,230	)
	Net cash provided (used) by investing activities	$	11,141		$	(24,566	)
Financing:	Cash Flows from Financing Activities:
	Repayments of notes payable		(1,270	)		(304	)
	Purchase of treasury stock		(50,391	)		(58,070	)
	Proceeds from the exercise of stock options		9,461			16,910
	Net cash used by financing activities	$	(42,200	)	$	(41,464	)
	Net effect of exchange rate changes		(1,828	)		76
	Net increase (decrease) in cash and cash equivalents		5,198			(22,058	)
	Cash and cash equivalents, beginning of period		47,156			186,717
	Cash and cash equivalents, end of period	$	52,354		$	164,659

IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow (Unaudited)

		Six Months Ended
		June 30, 2005			June 30, 2004
Free Cash Flow:	Net cash provided by operating activities	$	38,085		$	43,896
	Purchase of property and equipment		(10,508	)		(17,676	)
	Acquisition of equipment leased to customers		(1,278	)		(1,230	)
	Free cash flow	$	26,299		$	24,990
	Free cash flow indicates the cash generated from operations reduced by investments in capital and other long-term assets.  Free cash flow excludes financing activities, investments in monetary securities, and business acquisitions and divestitures.  We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business.  We believe this is a common financial measure useful to further evaluate the results of operations.